Payer Insights: MS [2016]: Bulletin #3
Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS); the impact of the launch delay of generic Copaxone 40mg/ml and potential steps that Teva could take to retain market share of its branded Copaxone; approaches to reimbursing Alkermes’ ALKS 8700 and opinions on ways by which Biogen could retain market share of Tecfidera.
Business Questions:
Business Questions:
- How do payers react to the recent approval of ocrelizumab?
- How is ocrelizumab likely to be covered in the US?
- How do US payers feel about ocrelizumab’s competitive pricing? Are there any apprehensions?
- How do payers react to the delay in launch of generic Copaxone 40mg/ml?
- According to payers, what can Teva do to retain its market share of branded Copaxone 40mg/ml?
- According to payers, what can Biogen do to retain market share of Tecfidera?
